Patents by Inventor Aline Van Pel

Aline Van Pel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for identifying individuals suffering from a cellular abnormality some of whose abnormal cells present complexes of HLA-A2/tyrosinase derived peptides, and methods for treating said individuals
    Patent number: 5747271
    Abstract: The invention relates to the identification of complexes of HLA-A2 and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: May 5, 1998
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5744316
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: January 17, 1996
    Date of Patent: April 28, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Bernard Lethe, Vincent Brichard, Aline Van Pel, Thomas Wolfel, Thierry Boon-Falleur
  • Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
    Patent number: 5620886
    Abstract: The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or "TRAP", is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: April 15, 1997
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Vincent Brichard, Aline Van Pel, Catia Traversari, Thomas W olfel, Thierry Boon-Falleur, Etienne De Plaen
  • Isolated, tyrosinase derived peptides and uses thereof
    Patent number: 5530096
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen molecules and tyrosinase derived peptides on the surfaces of abnormal cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: February 28, 1994
    Date of Patent: June 25, 1996
    Assignee: Ludwig Institute For Cancer Research
    Inventors: Thomas Wolfel, Aline Van Pel, Vincent Brichard, Thierry Boon-Falleur, Etienne DePlaen, Pierre Coulie, Jean-Christophe Renauld, Bernard Lethe
  • Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells
    Patent number: 5487974
    Abstract: The invention relates to the identification of complexes of human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase-derived peptide having the amino acid sequence Met Leu Leu Ala Val Leu Tyr Cys Leu Leu. The invention further relates to the detection of these complexes on the surface of abnormal cells and, in particular, on the surface of melanoma cells. The therapeutic and diagnostic ramifications of this observation are the subject of the invention.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: January 30, 1996
    Assignee: Ludwig Institute for Cancer-Research
    Inventors: Thierry Boon-Falleur, Vincent Brichard, Aline Van Pel, Etienne De Plaen, Pierre Coulie, Jean-Christope Renauld, Thomas Wolfel, Bernard Lethe
  • Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
    Patent number: 5342774
    Abstract: The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.
    Type: Grant
    Filed: December 12, 1991
    Date of Patent: August 30, 1994
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Thierry Boon, Pierre van der Bruggen, Benoit Van den Eynde, Aline Van Pel, Etienne De Plaen, Christophe Lurquin, Patrick Chomez, Catia Traversari